Episode: 194 - Douglas Kelly on the Value of Innovation and Breakthrough Designation
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Episode: 194 - Douglas Kelly on the Value of Innovation and Breakthrough Designation
-
Narrado por:
-
De:
Acerca de esta escucha
This month at Medtech Talk, co-host Justin Klein, co-founder and managing partner at Vensana Capital, debuts in his first episode with a discussion with Douglas Kelly, former deputy center director for science and chief scientist at the Center for Devices and Radiological Health at the FDA. Kelly talks about his time at the FDA and the fundamental changes he implemented to make a helpful impact on patients, including when the pandemic was at its peak. Kelly also shares his thoughts on the value of fostering innovation and the importance of breakthrough designation, as well as how to approach the process of advocacy and get in better alignment with shared priorities with the FDA, CMS, and other stakeholders
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones